COMMUNIQUÉS West-GlobeNewswire

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
16/01/2026
VANCOUVER, British Columbia and BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, [...]
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
16/01/2026
PHILADELPHIA, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid [...]
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
16/01/2026
CAMBRIDGE, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting [...]
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
16/01/2026
WALTHAM, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and [...]
Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Bid Price Deficiency
16/01/2026
HONG KONG, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) (the "Company"), a leading provider of over the counter (“OTC”) pharmaceutical cross-border e-commerce supply chain services in [...]
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
16/01/2026
CHASKA, Minn., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on January 14 [...]
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
16/01/2026
BRISBANE, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that [...]
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
16/01/2026
SAN CARLOS, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal [...]
Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease
16/01/2026
Designation based on clinical evidence supporting potential of ianalumab in Sjögren’s disease, including phase III trials 1 Distinction expedites development and review of treatments for serious conditions that may [...]
MicroTransponder Joins Innovators’ Network at American Heart Association Center for Health Technology & Innovation
16/01/2026
American Heart Association consortium advances development of evidence-based health tech solutions AUSTIN, Texas, Jan. 16, 2026 (GLOBE NEWSWIRE) -- MicroTransponder®, Inc. , a commercial-stage medical technology company [...]
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
16/01/2026
Company Announcement Based on the topline results from the EPCORE ® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss next steps COPENHAGEN, Denmark; January 16, 2026 – Genmab A/S (Nasdaq: GMAB [...]
Arch Biopartners Announces Appointment of Dr. Patrick Vink as Chairman of the Board
16/01/2026
TORONTO, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc . (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today the appointment of Dr. Patrick Vink as Chairman of the Company’s Board of [...]
Clene to Present at the Emerging Growth Conference
16/01/2026
SALT LAKE CITY, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company [...]
Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences
16/01/2026
PALI-2108 Abstracts Highlight Gut-Targeted PDE4B Inhibition and Translational Phase 1a Findings in Ulcerative Colitis Carlsbad, CA, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the [...]
SRx Health Solutions Invests in Common Stock of Opendoor Technologies
16/01/2026
NORTH PALM BEACH, Fla., Jan. 16, 2026 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the "Company") today announced that it has invested in the common stock of Opendoor Technologies Inc., a [...]
Glow Holdings, Inc. Introduces GlohCo as Its Healthtech Intelligence Platform
16/01/2026
HOUSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Glow Holdings, Inc. (OTC: GLOH), doing business as GlohCo, today announced its transition into a healthtech-focused public company following a corporate reset completed in 2025 [...]
OneMedNet Delivers a Real-World Data feed of 1.5M Patients consisting of 4M encounters
16/01/2026
MINNEAPOLIS, Jan. 16, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced that this month it has successfully delivered [...]
Baylor Genetics Supports Bipartisan House Bill to Broaden Medicaid Access to Genomic Sequencing for Children who Meet Medical Criteria
16/01/2026
Company joins forces with Genomic Answers for Children’s Health Alliance to clarify genomic sequencing as covered under Medicaid’s “Early and Periodic Screening, Diagnostic, and Treatment Services” HOUSTON, Jan. 16, [...]
Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million
16/01/2026
BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody [...]

Pages